“The current problem has exposed some structural weaknesses during the EU’s medicines source chain in addition to a higher dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides stated. She suggested that supply chain problems be resolved within an EU pharmaceutical method predicted to get released by the end of the